By contrast, large, randomized studies of PD-1 monotherapy have been negative: nivolumab did not improve overall survival versus bevacizumab in recurrent disease and nivolumab with radiotherapy did not surpass temozolomide-radiotherapy in newly diagnosed, MGMT-unmethylated glioblastoma (96, 97). The gene discussed is MGMT; the disease is glioblastoma.